Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

DESH RAKSHAK AUSHDHALAYA LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹26.90
at close · 23 Oct 2026
▲ 0.00 (+0.00%)

Latest filings

  1. Compliance Certificate for Dematerialisation Submitted for Q2 FY27 · Compliance
  2. Routine compliance certificate for share dematerialization for Q2 FY27 · Compliance
  3. Trading window closed from Oct 1, 2026 till Q2 results announcement · Compliance
All filings ↓
Ask Nexa about DESH RAKSHAK AUSHDHALAYA LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Manufactures Ayurvedic and herbal products and is based in Haridwar, having been established in 1901. The business is listed on BSE under scrip code 531521 and had FY26 revenue of Rs 7.1044 crore, with a net profit of Rs 0.5622 crore and an EBITDA margin of 19.6442%. Total assets stood at Rs 20.8884 crore at year-end. The cost structure is dominated by raw materials and packaging at 42% of revenue, followed by other operating expenses at 24% and employee costs at 14.5%, with depreciation at 6.1% and capex running at 14.4% of revenue. The company is small — 2,422 shareholders as of mid-2026 — and relies on working-capital lines, with outstanding borrowings of Rs 3.08 crore reported as of 31 March 2026. In September 2025, it raised Rs 2.77 crore through a preferential issue of 12.60 lakh shares at Rs 22 each, used for working capital (Rs 2.08 crore) and general corporate purposes (Rs 0.69 crore). The board has approved proposals to set up new branch offices within India and overseas, subject to regulatory approvals.

Operating scale
Year established
1901
Headquarters
Haridwar
Shareholders
2,422Jun 2026
Outstanding borrowings
Rs 3.08 crore31 Mar 2026
Preferential issue proceeds
Rs 2.77 crore (12.60 lakh shares at Rs 22)Sep 2025
Trade receivables increase
Rs 2.23 crore (drove negative operating cash flow of Rs 98.07 lakhs)FY26
Who pays it
Not specified in the available filings; sells Ayurvedic and herbal products to end consumers/distributors via branch offices
Biggest cost
Materials and packaging at 42% of revenue — the largest single cost line
Kind of business
Small-cap, niche Ayurvedic and herbal products manufacturer, working-capital-sensitive
Where it sits
BSE-listed Ayurvedic and herbal products maker based in Haridwar, established 1901, with FY26 revenue of Rs 7.1044 crore
Market Cap
₹15 Cr
P / E (TTM)
27.7×
EV / EBITDA
12.9×
Div Yield
—
Growth
1.5%▲
Revenue 5y CAGR
PAT +6.0% · EBITDA +7.8%
Quality
6.6%·
ROCE (5y median)
ROE 4.5% (5y median) · margin 19.6%
Leverage
0.21·
Debt / Equity · low
Net debt ₹2.65 Cr
Revenue FY21→FY26
1.1×▲
Margin +1.5 pts
₹7 Cr → ₹7 Cr
Cash conversion
0.25×▼
Operating cash ÷ profit · 5 yrs
₹1 Cr on ₹2 Cr
Moves on a normal day
4.97%·
Median daily move
Last 82 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#71/158
P/B#29/163
ROCE#134/183
ROE#121/166
Debt / Equity#98/166
EBITDA margin#38/165
Revenue growth#151/161
Profit growth#116/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Nothing stands out in the filed numbers.
Concerns
Slow revenue growth — 2% a year over 5 years
Returns on capital 6.6% (5-year median)
#134 of 183 in Pharmaceuticals on the latest reported figures
Over 5 years it reported ₹2.35 Cr of profit and ₹0.59 Cr of operating cash — 0.25×
Less than 60p of every ₹1 of profit arrived as cash
Heavy working capital — 277 days of cash tied up
Customers are taking longer to pay — 214 → 471 days of receivables
FY21 → FY26
EPS grew slower than profit — the share count rose (bonus or dilution)

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from DESH RAKSHAK AUSHDHALAYA LTD.'s filed financials and exchange disclosures

What does DESH RAKSHAK AUSHDHALAYA LTD. do?

DESH RAKSHAK AUSHDHALAYA LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is DESH RAKSHAK AUSHDHALAYA LTD. profitable?

Yes. Over the trailing twelve months DESH RAKSHAK AUSHDHALAYA LTD. reported a net profit of ₹0.55 Cr on revenue of ₹6.63 Cr.

Does DESH RAKSHAK AUSHDHALAYA LTD. pay a dividend?

Not in the latest reported year — DESH RAKSHAK AUSHDHALAYA LTD.'s dividend payout for FY26 was nil.

Is DESH RAKSHAK AUSHDHALAYA LTD. debt-free?

No. It reported borrowings of ₹2.80 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹2.65 Cr after cash. Debt stands at 0.21× equity. That is higher than 59% of its 166 Pharmaceuticals peers.

Is DESH RAKSHAK AUSHDHALAYA LTD. expensive compared with its peers?

On trailing P/E, DESH RAKSHAK AUSHDHALAYA LTD. ranks 71 of 158 in Pharmaceuticals — cheaper than 55% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the DESH RAKSHAK AUSHDHALAYA LTD. share price move in a day?

On a typical session DESH RAKSHAK AUSHDHALAYA LTD. moves 4.97% — that is the median absolute close-to-close move across its last 82 trading days. MarketPing measures each filing's price reaction against it.

Where can I track DESH RAKSHAK AUSHDHALAYA LTD.'s announcements?

Every NSE and BSE filing by DESH RAKSHAK AUSHDHALAYA LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.